| Name | Title | Contact Details |
|---|
Medical Claims Processing and Payer Solutions are Imagenets core business. Through our Paper to EDI, Adjudication, Claims Audit, and Contact Center solutions, Imagenet partners with each of our clients to ensure their compliance and business continuity needs are met, while helping implement bottom line efficiencies. All our solutions are Client Managed solutions, meaning your organization only supplies the business rules, and we respond with the tools, infrastructure, personnel, and subject matter experts, to accomplish the goals that your organization set out to accomplish. Our success is built upon our collaborative approach to engaging and delivering solutions to our trusted client partners. From our growing list of regional and locally staffed facilities, Imagenet performs as a natural extension of our client partners by delivering our solutions from local operating centers. Regional Facilities Located In: Arizona | California | Florida | Idaho | New Jersey | Pennsylvania | Texas | Washington
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
BlueScope Buildings North America, Inc. is a leading manufacturer of engineered building solutions. We custom-engineer and manufacture low-rise building envelopes using automated design technology to create an integrated building system. We are uniquely positioned to support facility expansion plans for corporations in logistics, beverage, manufacturing, mining, transportation, retail and other industries. BlueScope Buildings North America is the North American footprint of BlueScope Buildings. BlueScope Buildings is a business unit of public-traded BlueScope Ltd. (ASX: BSL)